Correction to: Programmable RNA Targeting Using CasRx in Flies,by Buchman,et al. The CRISPR Journal 2020;3(3)164–176;doi: 10.1089/crispr.2020.0018

In the June issue of The CRISPR Journal (vol. 3, no. 3; pp. 164–176), the article entitled “Programmable RNA Targeting Using CasRx in Flies, by Buchman, et al. requires correction.

The authors have updated the Author Disclosure Statement from:

“O.S.A and A.B. have a patent pending on this technology. All other authors declare that no competing financial interests exist.”

to

“O.S.A. is a founder of Agragene, Inc., with equity interest. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. O.S.A and A.B. have a patent pending on this technology. All other authors declare that no competing financial interests exist.”

The online version has been corrected to reflect this. The authors apologize for this error.